申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US05387710A1
公开(公告)日:1995-02-07
This invention relates to new ethanolamine derivatives having gut selective sympathomimetic and anti-pollakiuria activities and represented by the general formula [I]: ##STR1## wherein R.sup.1 is aryl or a heterocyclic group, each of which may be substituted with halogen, etc., R.sup.2 is hydrogen, halogen, nitro, hydroxy, lower alkyl optionally substituted with acyl, lower alkenyl optionally substituted with acyl, lower alkoxy optionally substituted with acyl, or amino optionally substituted with acyl(lower)alkyl, R.sup.3 is hydrogen, an N-protective group, or lower alkyl optionally substituted with lower alkylthio, n is an integer of 0 to 3, and a heavy solid line means a single bond or a double bond, provided that when n is 1, then 1) R.sup.1 is a condensed aromatic hydrocarbon group or a heterocyclic group, each of which may be substituted with halogen, etc., and the like, and pharmaceutically acceptable salts thereof to processes for the preparation thereof and to a pharmaceutical composition comprising the same.
这项发明涉及具有肠道选择性交感兴奋作用和抗多尿活性的新乙醇胺衍生物,其通式为[I]:其中R.sup.1是芳基或杂环基,每个都可以用卤素等取代,R.sup.2是氢、卤素、硝基、羟基、可选择用酰基取代的较低烷基、可选择用酰基取代的较低烯基、可选择用酰基取代的较低烷氧基、或者可选择用酰基(较低)烷基取代的氨基,R.sup.3是氢、N-保护基,或者可选择用较低烷基硫代取代的较低烷基,n是0到3的整数,重实线表示单键或双键,但当n为1时,则1)R.sup.1是缩合芳香烃基或杂环基,每个都可以用卤素等取代,等等,以及其药学上可接受的盐,以及制备它们的方法和包含相同的药物组合。